AUSTIN, Texas & MONTREAL--(BUSINESS WIRE)--Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, will present the first clinical data from ...
Presentations at CICON on Friday, Sep. 27, at 1:00 PM and 6:30 PM CEST and at ESMO on Saturday, Sep. 28, at 12:00 PM CEST AVID200 is a first-in-class, rationally designed inhibitor of TGF-beta 1 & 3, ...
TGF-ß, which has been studied for more than 30 years, has many jobs. One of them is helping to regulate the immune system. The immunotherapy drugs called checkpoint inhibitors have transformed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback